Key Takeaway: Maze Therapeutics has reported its financial results for Q2 2026, highlighting progress in several clinical trials. The Phase 2 HORIZON trial for MZE829 is on schedule, with data expected in late 2026 or early 2027. Additionally, the Phase 2 CIPheR trial for MZE782 in PKU has been initiated, and topline data is anticipated in 2027. The company also noted a strong balance sheet.
Market Sentiment Analysis
POSITIVE FACTORS
Enrollment in Phase 2 HORIZON trial is on track.
Initiation of Phase 2 CIPheR trial for MZE782 in PKU.
Strong financial position indicated by a robust balance sheet.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
1.8%
average across 3 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
MZE829
Phase 2 · Proteinuric Kidney Disease
Full Press Release Details
Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet
Frequently Asked Questions
What is the status of the Phase 2 HORIZON trial?
The Phase 2 HORIZON trial of MZE829 is on track, with data expected in late 2026 or early 2027.
When was the Phase 2 CIPheR trial initiated?
The Phase 2 CIPheR trial of MZE782 in PKU has been initiated, with enrollment ongoing.
What are the expected timelines for MZE782 trials?
Topline data for the Phase 2 CIPheR trial in PKU is expected in 2027, and the CKD trial is set for H1 2027.
How is Maze Therapeutics' financial position?
Maze Therapeutics reported a strong balance sheet in their Q2 2026 financial results.